tbuckley/cabot-search huggingface dataset:
Writing and speaking in medicine
Journal: BMJ (1976)

Advice centre for postgraduate medical educationThe three Councils for Postgraduate Medical Education (in England and Wales, Scotland, and Northern Ireland) are setting up a National Advice Centre to advise doctors on opportunities for postgraduate medical edu- cation and training in the United Kingdom.The centre will bring together several separate agencies at present helping doctors (part- icularly those from overseas).The service will incorporate that provided by the BMA for non-members and that run by the British Postgraduate Medical Federation for overseas doctors.The BMA will continue to advise its own members and those of affiliated organ- isations.The centre,
Postgraduate Courses for Physicians
Journal: JAMA (1960)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Early Detection in Childhood Lead Exposure Relies on Timely Testing—Reply
Authors: Marissa Hauptman, Justin K. Niles, Harvey W. Kaufman
Journal: JAMA Pediatrics (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF
Authors: Kieran F. Docherty, Joanne Simpson, Pardeep S. Jhund, Silvio E. Inzucchi, Lars Køber, Mikhail N. Kosiborod, Felipe A. Martinez, Piotr Ponikowski, Marc S. Sabatine, Olof Bengtsson, Mikaela Sjöstrand, Daniel Lindholm, Anna Maria Langkilde, Scott D. Solomon, John J.V. McMurray
Journal: JACC Heart Failure (2022)

The authors sought to examine the effect of dapagliflozin across the spectrum of risk in patients enrolled in DAPA-HF. In the DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial, the sodium-glucose cotransporter 2 inhibitor dapagliflozin decreased the risk of worsening HF events and cardiovascular death in patients with HF and reduced ejection fraction. The MAGGIC (Meta-analysis Global Group in Chronic Heart Failure) and the PARADIGM-HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure) PREDICT-HF (Risk of Events and Death in the Contemporary Treatment of Heart Failure) risk models were used to categorize patients according to risk score quintiles. The authors analyzed rates of the primary composite outcome of a worsening HF event or cardiovascular death, its components, and all-cause mortality according to risk quintile and whether risk modified the effect of dapagliflozin. The MAGGIC score was available for 4,740 of 4,744 patients in DAPA-HF (median score 22 [IQR: 18–25]). A1-point increase was associated with an 8.2% (95% CI: 6.9%–9.4%) higher relative risk of the primary endpoint (P < 0.001). The benefit of dapagliflozin over placebo for the primary endpoint was similar across the spectrum of MAGGIC risk score (interaction P = 0.71). Applying the overall relative risk reduction (26%) with dapagliflozin added to standard therapy resulted in 7 fewer patients in the highest MAGGIC risk quintile experiencing a primary outcome, compared with 2 in the lowest quintile, per 100 person-years of treatment. The findings with PREDICT-HF were similar, although this model led to better risk discrimination. The benefits of dapagliflozin were consistent across the broad spectrum of baseline risk in DAPA-HF.
TCT-14 Preventive versus Culprit Only Percutaneous Coronary Intervention in ST Elevation Myocardial Infarction Patients with Multivessel Disease: A Meta Analysis
Authors: Yeo-Jeong Song, Jae-Sik Jang, Byeong-Woo Kim, Han-Young Jin, Jeong-Sook Seo, Tae-Hyun Yang, Dae-Kyeong Kim, Dong-Soo Kim
Journal: Journal of the American College of Cardiology (2014)
Combined coronary stent treatment of unprotected left main disease and severe coronary lesions located at remote sites Alfonso Medina, Jose Suarez de Lezo, Manuel Pan, Miguel Romero, Enrique Hernandez, Djordje Pavlovic, Jose Segura, Juan R. Siles, Ricardo Huerta, Soledad Ojeda, Carmen Adamuz, Jose R. Ortega. Negrin Hospital, Las PAlmas, Spain, Reina Sofia Hospital, Cordoba, Spain
Journal: Journal of the American College of Cardiology (2001)
The efficacy of multimodal therapy with pacing, cardioverson and amiodarone to maintain sinus rhythm in patients with ?chronic? atrial fibrillation and congestive heart failure Scott R. Kirby, Florin T. Degeratu, Eric J. Rashba, Stephen R. Shorofsky, Robert W. Peters, Michael R. Gold. University of Maryland, Baltimore, MD
Journal: Journal of the American College of Cardiology (2001)
Severe hypoxia is a typical characteristic of human hepatocellular carcinoma: Scientific fact or fallacy?
Authors: Thorsten Cramer, Peter Vaupel
Journal: Journal of Hepatology (2022)

Hepatocellular carcinoma (HCC) is characterised by a robust resistance to therapy, resulting in the very poor prognosis usually seen in patients with unresectable HCC. A thorough understanding of the molecular and cellular pathogenesis of HCC is of paramount importance for the identification of more effective treatment options. As hypoxia in tumours is associated with the malignant phenotype, molecules involved in the hypoxic response are being investigated as potential targets for cancer therapy. One key hallmark of human HCC is the hypervascularisation and arterialisation of the tumour's blood supply. Hypoxia being a strong inducer of neo-angiogenesis, it was hypothesised over 20 years ago that reduced oxygen levels in human HCC are a crucial feature of this deadly disease. However, while there is a considerable body of literature espousing the presumed functional relevance of hypoxia in HCC, direct measurements of oxygen partial pressures or O2 concentrations in human HCCs have yet to be performed. This narrative review seeks to demonstrate how overinterpretation of in vitro experiments and incorrect citations have resulted in HCCs being perceived as severely hypoxic tumours.
Antenatal screening for syphilis should not be abandoned
Journal: BMJ (1998)

Antenatal screening for syphilis should not be abandoned Antenatal screening for syphilis in the United Kingdom is routine but lacks any formal or evidence based policy.On p 1617 Hurtig et al report on the first national surveys of syphilis in pregnancy and congenital syphilis.Over three years 121 of the 139 pregnant women treated for syphilis by genitourinary medicine specialists were detected through antenatal screening.Women from ethnic minority groups, who were born abroad, or who were living in London were overrepresented, but cases also occurred in white women born in the United Kingdom and living outside London.Seventeen children were found with presumptive or possible congenital syphilis; mothers not receiving antenatal care or late booking was a risk factor.The authors conclude that abandoning or targeting screening is inadvisable.
Formation and Reactions of Negative Ions Relevant to Chemical Ionization Mass Spectrometry. I. CI Mass Spectra of Organic Compounds Produced by F - Reactions
Authors: T. O. Tiernan, C. Chang, C. C. Cheng
Journal: Environmental Health Perspectives (1980)

A systematic study of the negative-ion chemical ionization mass spectra produced by the reaction of F-with a wide variety of organic compounds has been accomplished.A time-of-flight mass spectrometer fitted with a modified high pressure ion source was employed for these ex- periments.The F-reagent ion was generated from CF3H or NF3, typically at an ion source pressure of 100 ,um.In pure NF3, F-is the major ion formed and constitutes more than 90% of the total ion intensity.While F-is also the major primary ion formed in pure CF3H, it under- goes rapid ion-molecule reactions at elevated source pressures, yielding (HF),F-(n -1-3) ions, which makes CF3H less suitable as a chemical ionization reagent gas.Among the organic compounds investigated were carboxylic acids, ketones, aldehydes, esters, alcohols, phenols, halides, nitriles, nitrobenzene, ethers, amines and hydrocarbons.An intense (M -1)-ion was observed in the F-chemical ionization mass spectra of carboxylic acids, ketones, aldehydes and phenols.Alcohols yield only (M + F)-ions upon reaction with F-.A weaker (M + F)-ion was also detected in the F-chemical ionization spectra of carboxylic acids, aldehydes, ketones and nitriles.The F-chemical ionization mass spectra of esters, halides, nitriles, nitrobenzene and ethers are characterized primarily by the ions, RCOO-, X-, CN-, NO2-, and OR-, respectively.In addition, esters show a very weak (M -1)-ion (except formates).In the F-chemical ioniza- tion spectra of some aliphatic alkanes and o-xylene, a very weak (M + F)-ion was observed.Amines and aliphatic alkenes exhibit only insignificant fragment ions under similar conditions, while aromatic hydrocarbons, such as benzene and toluene are not reactive at all with the F- ion.The mechanisms of the various reactions mentioned are discussed, and several experimental complications are noted.In still other studies, the effects of varying several experimental parameters, including source pressure, relative proportions of the reagent and analyte, and other ion source parameters, on the observed chemical ionization mass spectra were also inves- tigated.In a mixture of NF3 and n-butanol, for example, the ratio of the intensities of the ions characteristic of the alcohol to that of the (HF),,F-ion was found to decrease with increasing sample pressure, with increasing NF3 pressure, and with increasing electron energy.No significant effects on the spectra were observed to result from variation of the source repeller field or the source temperature.The addition of argon to the source as a potential moderator did not alter the F-chemical ionization spectrum significantly, but the use of oxygen appears to inhibit formation of the (HF),Fcluster ion.The advantages of using F-as a chemical ionization re- agent are discussed, and comparisons are made with other reagent ions.
HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta‐analysis
Authors: Ian Lockart, Malcolm G. H. Yeo, Behzad Hajarizadeh, Gregory J. Dore, Mark Danta
Journal: Hepatology (2022)

Abstract Background and Aims HCV cure reduces but does not eliminate the risk of HCC. HCC surveillance is recommended in populations where the incidence exceeds 1.5% per year. In cirrhosis, HCC surveillance should continue after HCV cure, although it is uncertain if this should be indefinite. For patients with advanced fibrosis (F3), guidelines are inconsistent in their recommendations. We evaluated the incidence of HCC after HCV cure among patients with F3 fibrosis or cirrhosis. Approach and Results This systematic review and meta‐analysis identified 44 studies (107,548 person‐years of follow‐up) assessing the incidence of HCC after HCV cure among patients with F3 fibrosis or cirrhosis. The incidence of HCC was 2.1 per 100 person‐years (95% CI, 1.9–2.4) among patients with cirrhosis and 0.5 per 100 person‐years (95% CI, 0.3–0.7) among patients with F3 fibrosis. In a meta‐regression analysis among patients with cirrhosis, older age (adjusted rate ratio [aRR] per 10‐year increase in mean/median age, 1.32; 95% CI, 1.00–1.73) and prior decompensation (aRR per 10% increase in the proportion of patients with prior decompensation, 1.06; 95% CI, 1.01–1.12) were associated with an increased incidence of HCC. Longer follow‐up after HCV cure was associated with a decreased incidence of HCC (aRR per year increase in mean/median follow‐up, 0.87; 95% CI, 0.79–0.96). Conclusions Among patients with cirrhosis, the incidence of HCC decreases over time after HCV cure and is lowest in patients with younger age and compensated cirrhosis. The substantially lower incidence in F3 fibrosis is below the recommended threshold for cost‐effective screening. The results should encourage the development of validated predictive models that better identify at‐risk individuals, especially among patients with F3 fibrosis.
INTRA-OCULAR FOREIGN BODIES
Journal: JAMA (1929)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Commentaire de travail de D. P. Hurlstone et al., pp. 110
Journal: Endoscopy (2008)

See also:EMR using dextrose solution versus sodium hyaluronate for colorectal Paris type I and 0-II lesions: a randomized endoscopist-blinded studyEndoscopy 2008; 40(02): 110-114DOI: 10.1055/s-2007-966987
Revacularization in patients with unstable coronary artery disease: Is there still a need for CABG? Elisabeth Stahle, Odd Geiran, Bo Lagerqvist, Hans Pilegaard, Rolf Svedjeholm, Eva Swahn, Lars Wallentin. Dept Thoracic and Cardiovascular Surgery, University hospital, Uppsala, Sweden, Dept Cardiology, University hospital, Uppsala, Sweden
Journal: Journal of the American College of Cardiology (2001)
BELGIUM
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Survival of stage III colon cancer patients with adjuvant chemotherapy: Experience from a specialized cancer institute in Latinoamerica - Peru.
Authors: Eder Christian Veramendi Cabana, Jorge Antonio Cotito Izquierdo, Jackeline Macetas, Mariana Serrano, Cristian Pacheco, Victor Castro, Jhajaira M Araujo, Paola Catherine Montenegro
Journal: Journal of Clinical Oncology (2022)

204 Background: In Peru, colon cancer is the 5th most common cause of cancer and the sixth most deadly. Currently, surgery remains as the only curative therapy, however, there is risk of recurrence. Adjuvant chemotherapy has become a useful tool to improve progression-free survival (PFS) and overall survival (OS). In this study, we determine the current survival of our stage III colon cancer patients, submitted to adjuvant chemotherapy, and if this is similar to the evidence seen in large international studies; also, we analyze if delay of adjuvant chemotherapy has impact on survival. Methods: This descriptive cross-sectional study involved 162 patients with stage III colon cancer who underwent a resection surgery and received adjuvant fluoropyrimidine-based chemotherapy. They were evaluated, according to the TNM classification (tumor, nodule), as low risk (T1-T3, N1) and high risk (T4, N2). We also classified patients, according to the weeks of delay from surgery to adjuvant chemotherapy, into subgroups of 6, 8 and 10 weeks. Results: The mean age was 63.7 years, 63 patients were women (38.9%), 99 patients (61.1%) were men. Only 38.3% of patients started adjuvant chemotherapy in the first 6 weeks after surgery, and 85.8% of patients, in the first 10 weeks; the median time from surgery to initiation of adjuvant chemotherapy was 7.0 weeks. We estimated that, at 3 years, the median PFS is 73.5% (95% CI: 65.8-82.1). The 3-year PFS in the low-risk group was 82.9% (95% CI: 72.3-95.0) and 67.3% (95% CI: 57.2-79.2) in the high-risk group. It was estimated that at 3 years, the median OS is 81.1% (95% CI: 75.2-87.5). The 3-year OS in the low-risk group was 87.9% (95% CI: 80.4-96.2) and 76.0% (95% CI: 67.8-85.3) in the high-risk group. Conclusions: The PFS and OS in Peruvian population is similar to data evidenced in international historical studies such as the IDEA trial. This study, also, suggests that starting adjuvant treatment within 10 weeks does not present an impact on OS and PFS in our population.
CHRONIC VILLOUS POLYARTHRITIS.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LGBTQ+ Inclusivity in Surgery—A Call to Action
Authors: Jordan A. McKean, Kelly M. Herremans, Crystal N. Johnson-Mann
Journal: JAMA Surgery (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
The History of Blood Gases, Acids and Bases.
Journal: Annals of Internal Medicine (1988)

Reviewscross-reference between papers.Worse, editorial indulgence has left several of them substantially overlapping in scope, if not mutually contradictory-so that Nutton does much of the job of three other contributors rather more cogently than they can themselves.The weakness of these three emphasizes a more general failure to match painstaking scholarship with thoughtful interpretation.Contented reference to "tradition and empiricism" is not enough: by now we ought to be questioning the sensitivity of that formulation, not merely endorsing it.